{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:23:34Z","timestamp":1793622214798,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.yexcr.2026.114946","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:10:16Z","timestamp":1771459816000},"page":"114946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["KPT-8602 combined with IFN-\u03b3 released ZBP1-PANoptosome to inhibit the progression of primary central nervous system lymphoma"],"prefix":"10.1016","volume":"457","author":[{"given":"Wei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-023-00439-0","article-title":"Primary central nervous system lymphoma","volume":"9","author":"Ferreri","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"Suppl 4","key":"10.1016\/j.yexcr.2026.114946_bib2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib3","first-page":"49","article-title":"CACA primary central nervous system lymphoma integrated diagnosis and treatment guidelines (abridged version)","volume":"42","author":"Pu","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.yexcr.2026.114946_bib4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s10143-018-0946-0","article-title":"The role of surgery in intracranial PCNSL","volume":"41","author":"Jahr","year":"2018","journal-title":"Neurosurg. Rev."},{"issue":"2","key":"10.1016\/j.yexcr.2026.114946_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/ejh.13639","article-title":"Treatment patterns and disease course of previously untreated Primary central nervous system lymphoma: feasibility of MTX-based regimens in clinical routine","volume":"107","author":"Sieg","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.yexcr.2026.114946_bib6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fcimb.2019.00406","article-title":"ZBP1 and TAK1: master regulators of NLRP3 Inflammasome\/Pyroptosis, apoptosis, and necroptosis (PAN-optosis)","volume":"9","author":"Malireddi","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.yexcr.2026.114946_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122158","article-title":"PANoptosis: emerging mechanisms and disease implications","volume":"333","author":"Qi","year":"2023","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/molecules28010052","article-title":"ZBP1-Mediated necroptosis: mechanisms and therapeutic implications","volume":"28","author":"Chen","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imr.12534","article-title":"Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases","volume":"277","author":"Man","year":"2017","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.yexcr.2026.114946_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.chom.2019.09.004","article-title":"DAI\/ZBP1\/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by Murine cytomegalovirus vIRA","volume":"26","author":"Upton","year":"2019","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib11","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1038\/s41467-021-23004-3","article-title":"ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer","volume":"12","author":"Baik","year":"2021","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.yexcr.2026.114946_bib12","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191913","article-title":"Sensing of endogenous nucleic acids by ZBP1 induces keratinocyte necroptosis and skin inflammation","volume":"217","author":"Devos","year":"2020","journal-title":"J. Exp. Med."},{"issue":"Supplement_1","key":"10.1016\/j.yexcr.2026.114946_bib13","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood-2019-124136","article-title":"Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with higher-risk myelodysplastic syndrome","volume":"134","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2026.114946_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114402","article-title":"XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma","volume":"160","author":"Wang","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"13","key":"10.1016\/j.yexcr.2026.114946_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136676","article-title":"Nuclear export inhibitor KPT-8602 synergizes with PARP inhibitors in escalating apoptosis in castration resistant cancer cells","volume":"22","author":"Uddin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.yexcr.2026.114946_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929005","article-title":"Double-edged effects of interferons on the regulation of cancer-immunity cycle","volume":"10","author":"Zhang","year":"2021","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.yexcr.2026.114946_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109858","article-title":"ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis","volume":"37","author":"Karki","year":"2021","journal-title":"Cell Rep."},{"issue":"10","key":"10.1016\/j.yexcr.2026.114946_bib19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00018-022-04564-z","article-title":"Single cell analysis of PANoptosome cell death complexes through an expansion microscopy method","volume":"79","author":"Wang","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.yexcr.2026.114946_bib20","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s12013-023-01135-2","article-title":"Nuclear export inhibitors selinexor (KPT-330) and eltanexor (KPT-8602) provide a novel therapy to reduce tumor growth by induction of PANoptosis","volume":"81","author":"Camilli","year":"2023","journal-title":"Cell Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41419-020-03249-4","article-title":"The critical role of T cells in glucocorticoid-induced osteoporosis","volume":"12","author":"Song","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexcr.2026.114946_bib22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fonc.2020.00682","article-title":"The role of BAFF-R signaling in the growth of primary central nervous system lymphoma","volume":"10","author":"Zhou","year":"2020","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.yexcr.2026.114946_bib23","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V128.22.3298.3298","article-title":"Synergistic anti-tumor effect of KPT-8602, a second generation selective inhibitor of nuclear export (SINE) compound, and Panobinostat, a pan-histone deacetylase (HDAC) inhibitor in multiple myeloma","volume":"128","author":"Argueta","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.yexcr.2026.114946_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007402","article-title":"Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment","volume":"11","author":"Lin","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.yexcr.2026.114946_bib25","article-title":"New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexcr.2026.114946_bib26","article-title":"Overcoming the blood-brain barrier by using a multistage exosome delivery system to inhibit central nervous system lymphoma","volume":"41","author":"Liu","year":"2022","journal-title":"Nanomedicine"},{"issue":"12","key":"10.1016\/j.yexcr.2026.114946_bib27","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1111\/jcpt.13791","article-title":"Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma","volume":"47","author":"Sun","year":"2022","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.yexcr.2026.114946_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100770","article-title":"Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function","volume":"57","author":"Gao","year":"2021","journal-title":"Drug Resist. Updates"},{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","article-title":"The BCL-2 arbiters of apoptosis and their growing role as cancer targets","volume":"25","author":"Adams","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.yexcr.2026.114946_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2023.102348","article-title":"PANoptosome signaling and therapeutic implications in infection: central role for ZBP1 to activate the inflammasome and PANoptosis","volume":"83","author":"Karki","year":"2023","journal-title":"Curr. Opin. Immunol."},{"issue":"4","key":"10.1016\/j.yexcr.2026.114946_bib31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41423-019-0237-x","article-title":"ZBP1 mediates interferon-induced necroptosis","volume":"17","author":"Yang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"74","key":"10.1016\/j.yexcr.2026.114946_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo6294","article-title":"ZBP1-dependent inflammatory cell death, PANoptosis, and cytokine storm disrupt IFN therapeutic efficacy during coronavirus infection","volume":"7","author":"Karki","year":"2022","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.114946_bib33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","article-title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","volume":"31","author":"Etchin","year":"2017","journal-title":"Leukemia"},{"issue":"105","key":"10.1016\/j.yexcr.2026.114946_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ado1710","article-title":"Epidermal ZBP1 stabilizes mitochondrial Z-DNA to drive UV-induced IFN signaling in autoimmune photosensitivity","volume":"10","author":"Klein","year":"2025","journal-title":"Sci. Immunol."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726000637?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726000637?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T02:59:44Z","timestamp":1773457184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482726000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0014482726000637"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.114946","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KPT-8602 combined with IFN-\u03b3 released ZBP1-PANoptosome to inhibit the progression of primary central nervous system lymphoma","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.114946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114946"}}